Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KISS1R | Q969F8 | 1/20 | 0.52 |
| ▸ | RAMP3 | O60896 | 7/20 | 0.51 |
| ▸ | CALCR | P30988 | 7/20 | 0.51 |
| ▸ | CCNA2 | P20248 | 2/20 | 0.49 |
| ▸ | CDK2 | P24941 | 2/20 | 0.49 |
| ▸ | CCNA1 | P78396 | 2/20 | 0.49 |
| ▸ | NPBWR1 | P48145 | 2/20 | 0.49 |
| ▸ | APLNR | P35414 | 2/20 | 0.48 |
| ▸ | SLC15A2 | Q16348 | 1/20 | 0.47 |
| ▸ | GRPR | P30550 | 4/20 | 0.47 |
| ▸ | EGFR | P00533 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29419646 | 0.85 | CCNA2 (0.58) | CCNA2CDK2CCNA1NPBWR1APLNR | |
| SCHEMBL29596006 | 0.80 | NR3C1 (0.56) | RAMP3CALCRNPBWR1 | |
| SCHEMBL29351251 | 0.80 | SLC15A2 (0.52) | CCNA2CDK2CCNA1NPBWR1SLC15A2 | |
| SCHEMBL23083920 | 0.79 | CCNA2 (0.58) | CCNA2CDK2CCNA1SLC15A2 | |
| SCHEMBL29351692 | 0.78 | SLC15A2 (0.76) | CCNA2CDK2CCNA1SLC15A2 | |
| SCHEMBL31332077 | 0.76 | NR3C1 (0.60) | — | |
| SCHEMBL30903543 | 0.76 | CYP3A4 (0.47) | CCNA2CDK2CCNA1SLC15A2 | |
| SCHEMBL29368268 | 0.76 | SLC15A2 (0.53) | SLC15A2 | |
| SCHEMBL11054592 | 0.75 | RAMP3 (0.50) | RAMP3CALCRAPLNR | |
| SCHEMBL27624700 | 0.75 | SLC15A2 (0.51) | SLC15A2GRPR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-114901698-B | Compositions and uses of engineered monoclonal antibodies against tumor immunosuppressive factors | 纳夫罗根公司 | 2024-08-06 | — | — | CN | disclosed |
| CN-110612113-B | Gene therapy for haploid insufficiency | 加利福尼亚大学董事会 | 2024-03-26 | — | — | CN | disclosed |
| CN-110036119-B | Ovarian cancer biomarker and application thereof | 丰宥科技股份有限公司 | 2024-01-23 | — | — | CN | disclosed |
| CN-117295819-A | Compositions and methods for inhibiting expression of complement component 3 | 阿斯利康(爱尔兰)有限公司 | 2023-12-26 | — | — | CN | disclosed |
| CN-113884684-B | Construction method of active tuberculosis multiunit chemical integration marker, kit and detection model | 上海依赛洛森生物医药有限公司 | 2023-09-15 | — | — | CN | disclosed |
| CN-116235054-A | Method for determining a subject's predisposition from a light-medium COVID-19 disease course to a severe or critical disease course | 赛欧米克斯股份有限公司 | 2023-06-06 | — | — | CN | disclosed |
| CN-115997127-A | Detection of complement proteins | 曼寿医药有限公司 | 2023-04-21 | — | — | CN | disclosed |
| CN-115066615-A | Determination support information generation method, determination support information generation system, and information processing device | 株式会社MCBI | 2022-09-16 | — | — | CN | disclosed |
| CN-114901698-A | Composition and use of engineered monoclonal antibodies against tumor immunosuppressive factors | 纳夫罗根公司 | 2022-08-12 | — | — | CN | disclosed |
| CN-114487428-A | Application of urine complement C3 protein and polypeptide fragment thereof in gestational diabetes and neonatal evaluation | 首都医科大学附属北京世纪坛医院 | 2022-05-13 | — | — | CN | disclosed |